Key result
In patients with advanced heart failure undergoing cardiac resynchronization therapy, advanced age did not significantly affect clinical response or cardiovascular mortality.
Why the study?
Cardiac resynchronization therapy is a valid option for heart failure, but the elderly population was not well represented in guidelines.
Cohort (n=249)
No
Absolute Event Rate: 68.5% vs 52.3%
p-value: p=ns
Cardiac resynchronization therapy provides similar clinical response and cardiovascular mortality benefits in older and very old patients compared to younger patients, with a comparable safety profile.
No takes yet. Share an insight, caveat, or question.
CRT response and CV mortality similar across ages; leaves open whether very old age independently raises total mortality.
Camanho et al. (2019) conducted a cohort in Heart failure (n=249). Advanced age (≥75 years) vs. Age <65 years was evaluated on Clinical response (improvement in functional class and at least 1 echocardiographic criterion) (p=ns). In patients with advanced heart failure undergoing cardiac resynchronization therapy, advanced age did not significantly affect clinical response or cardiovascular mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: